Search

Your search keyword '"Reindl, Caroline"' showing total 16 results
Start Over Author "Reindl, Caroline" Search Limiters Available in Library Collection
16 results on '"Reindl, Caroline"'

2. Age of epilepsy onset as modulating factor for naming deficit after epilepsy surgery: a voxel-based lesion-symptom mapping study

Author

Reindl, Caroline, Walther, Katrin, Allgäuer, Anna-Lena, Lang, Johannes D., Welte, Tamara M., Stritzelberger, Jenny, Gollwitzer, Stephanie, Schwarz, Michael, Trollmann, Regina, Madzar, Dominik, Knott, Michael, Doerfler, Arnd, Seifert, Frank, Rössler, Karl, Brandner, Sebastian, Rampp, Stefan, Schwab, Stefan, and Hamer, Hajo M.

Published
2023
Full Text
View/download PDF

4. Resection of dominant fusiform gyrus is associated with decline of naming function when temporal lobe epilepsy manifests after the age of five: A voxel-based lesion-symptom mapping study

Author

Reindl, Caroline, Allgäuer, Anna-Lena, Kleiser, Benedict A., Onugoren, Müjgan Dogan, Lang, Johannes D., Welte, Tamara M., Stritzelberger, Jenny, Winder, Klemens, Schwarz, Michael, Gollwitzer, Stephanie, Trollmann, Regina, Rösch, Julie, Doerfler, Arnd, Rössler, Karl, Brandner, Sebastian, Madžar, Dominik, Seifert, Frank, Rampp, Stefan, Hamer, Hajo M., and Walther, Katrin

Published
2022
Full Text
View/download PDF

7. Status epilepticus in patients with glioblastoma: Clinical characteristics, risk factors, and epileptological outcome

Author

Stritzelberger, Jenny, primary, Gesmann, Anna, additional, Fuhrmann, Imke, additional, Balk, Stefanie, additional, Reindl, Caroline, additional, Madžar, Dominik, additional, Uhl, Martin, additional, Welte, Tamara M., additional, Brandner, Sebastian, additional, Eisenhut, Felix, additional, Dörfler, Arnd, additional, Coras, Roland, additional, Adler, Werner, additional, Schwab, Stefan, additional, Putz, Florian, additional, Fietkau, Rainer, additional, Distel, Luitpold, additional, and Hamer, Hajo M., additional

Published
2023
Full Text
View/download PDF

12. Antiseizure medication and perceived “fair” cost allocation: A factorial survey among neurologists, persons with epilepsy, their relatives, and a control group

Author

Stritzelberger, Jenny, primary, Walther, Katrin, additional, Olmes, David, additional, Gollwitzer, Stefanie, additional, Graf, Wolfgang, additional, Welte, Tamara M., additional, Lang, Johannes D., additional, Reindl, Caroline, additional, Schwab, Stefan, additional, Kriwy, Peter, additional, and Hamer, Hajo M., additional

Published
2022
Full Text
View/download PDF

13. Phenobarbital in super‐refractory status epilepticus (PIRATE): A retrospective, multicenter analysis.

Author

Kunst, Stefan, Rojo, Mikel, Schmidbauer, Moritz L., Pelz, Johann O., Mueller, Annekatrin, Minnerup, Jens, Meyer, Lennart, Madžar, Dominik, Reindl, Caroline, Madlener, Marie, Malter, Michael, Neumann, Bernhard, and Dimitriadis, Konstantinos

Subjects
STATUS epilepticus, NOSOCOMIAL infections, PHENOBARBITAL, ANAPHYLAXIS, HOSPITAL mortality
Abstract

Objective: Super‐refractory status epilepticus (SRSE) is an enduring or recurring SE after 24 h or more of general anesthesia. This study aimed to evaluate the efficacy and safety of phenobarbital (PB) for the treatment of SRSE. Methods: This retrospective, multicenter study included neurointensive care unit (NICU) patients with SRSE treated with PB between September 2015 and September 2020 from six participating centers of the Initiative of German NeuroIntensive Trial Engagement (IGNITE) to evaluate the efficacy and safety of PB treatment for SRSE. The primary outcome measure was seizure termination. In addition, we evaluated maximum reached serum levels, treatment duration, and clinical complications using a multivariate generalized linear model. Results: Ninety‐one patients were included (45.1% female). Seizure termination was achieved in 54 patients (59.3%). Increasing serum levels of PB were associated with successful seizure control (per μg/mL: adjusted odds ratio [adj.OR] = 1.1, 95% confidence interval [CI] 1.0–1.2, p <.01). The median length of treatment in the NICU was 33.7 [23.2–56.6] days across groups. Clinical complications occurred in 89% (n = 81) of patients and included ICU‐acquired infections, hypotension requiring catecholamine therapy, and anaphylactic shock. There was no association between clinical complications and treatment outcome or in‐hospital mortality. The overall average modified Rankin scale (mRS) at discharge from the NICU was 5 ± 1. Six patients (6.6%) reached mRS ≤3, of whom five were successfully treated with PB. In‐hospital mortality was significantly higher in patients in whom seizure control could not be achieved. Significance: We observed a high rate in attainment of seizure control in patients treated with PB. Success of treatment correlated with higher dosing and serum levels. However, as one would expect in a cohort of critically ill patients with prolonged NICU treatment, the rate of favorable clinical outcome at discharge from the NICU remained extremely low. Further prospective studies evaluating long‐term clinical outcome of PB treatment as well as an earlier use of PB at higher doses would be of value. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Additional file 2: of Impact of timing of continuous intravenous anesthetic drug treatment on outcome in refractory status epilepticus

Author

MadĹžar, Dominik, Reindl, Caroline, Giede-Jeppe, Antje, Bobinger, Tobias, SprĂźgel, Maximilian, Knappe, Ruben, Hamer, Hajo, and Huttner, Hagen

Subjects
nervous system
Abstract

Table S2. Comparison of follow-up times between patients with early versus late continuous intravenous anesthetic drug (cIVAD) treatment in the subgroups defined by Status Epilepticus Severity Score (STESS) and its components. (DOCX 14 kb)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results